Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer

Sanne Ten Hoorn, Linda Mol, Dirkje W Sommeijer, Lisanne Nijman, Tom van den Bosch, Tim R de Back, Bauke Ylstra, Erik van Dijk, Carel J M van Noesel, Roy J Reinten, Iris D Nagtegaal, Miriam Koopman, Cornelis J A Punt, Louis Vermeulen

Research output: Contribution to journalArticleAcademicpeer-review

1 Downloads (Pure)

Abstract

BACKGROUND: Here we present updated survival of the CAIRO2 trial and assessed whether the addition of anti-EGFR to anti-VEGF therapy could still be an effective treatment option for patients with extended RAS/BRAF wildtype and left-sided metastatic colorectal cancer (mCRC).

MATERIALS AND METHODS: Retrospective updated survival and extended RAS and BRAF V600E mutational analysis were performed in the CAIRO2 trial, a multicenter, randomized phase III trial on the effect of adding cetuximab to a combination of capecitabine, oxaliplatin (CAPOX), and bevacizumab in mCRC.

RESULTS: Updated survival analysis confirmed that the addition of cetuximab did not provide a benefit on either progression free (PFS) or overall survival (OS) in the intention-to-treat population. With the extended mutational analyses 31 KRAS, 31 NRAS and 12 BRAF V600E additional mutations were found. No benefit of the addition of cetuximab was observed within the extended wildtype group, even when selecting only left-sided tumors (PFS HR 0.96, p = 0.7775). However, compared to the original trial an increase of 6.5 months was seen for patients with both extended wildtype and left-sided tumors (median OS 28.6 months).

CONCLUSION: Adding cetuximab to CAPOX and bevacizumab does not provide clinical benefit in patients with mCRC, even in the extended wildtype group with left-sided tumors. However, in the extended wildtype group we did observe clinically relevant higher survival compared to the initial trial report, indicating that it is important to analyze a broader panel of RAS and BRAF variants using more recent sequencing techniques when assessing survival benefit after anti-EGFR therapy.

Original languageEnglish
Pages (from-to)67-75
Number of pages9
JournalClinical colorectal cancer
Volume22
Issue number1
Early online date5 Dec 2022
DOIs
Publication statusPublished - Mar 2023

Keywords

  • Gastrointestinal cancer, Adjuvant chemotherapy, Anti-EGFR, Anti-VEGF
  • Molecular subtypes

Fingerprint

Dive into the research topics of 'Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer'. Together they form a unique fingerprint.

Cite this